Related Experiment Video
Updated: Jun 26, 2026
14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Montelukast sodium for exercise-induced asthma.
Fernando Maria de Benedictis1, Silvia Vaccher, Diletta de Benedictis
1Department of Pediatrics, Salesi Children's Hospital, Ancona, Italy. debenedictis@ao-salesi.marche.it
Drugs of Today (Barcelona, Spain : 1998)
|January 31, 2009
Summary
Montelukast effectively prevents exercise-induced bronchoconstriction (EIB) in children with asthma. This medication offers reliable protection without diminishing effectiveness over time, supporting active lifestyles.
Area of Science:
- Pediatric Pulmonology
- Allergy and Immunology
- Pharmacology
Background:
- Exercise is a primary trigger for bronchospasm in children with asthma, leading to exercise-induced bronchoconstriction (EIB).
- EIB affects a significant percentage of children with asthma and allergic rhinitis, impacting their ability to participate in physical activities.
- Cysteinyl leukotrienes are key mediators in the inflammatory pathways contributing to EIB.
Purpose of the Study:
- To evaluate the efficacy of montelukast sodium in preventing exercise-induced bronchoconstriction (EIB) in pediatric populations.
- To assess the long-term effectiveness and potential for tolerance development with chronic montelukast treatment for EIB.
Main Methods:
- Review of studies evaluating single-dose and regular-treatment regimens of montelukast for EIB prevention.
- Analysis of data from both adult and pediatric participants across various clinical trials.
- Assessment of montelukast's impact on airway hyperresponsiveness following exercise challenges.
Main Results:
- Montelukast sodium demonstrated significant protective effects against EIB in both single-dose and chronic treatment protocols.
- Studies indicated that continuous montelukast therapy does not lead to a loss of its bronchoprotective efficacy over time.
- The drug's consistent efficacy is particularly beneficial for children with unpredictable activity patterns.
Conclusions:
- Montelukast is an effective therapeutic option for preventing EIB in children with asthma.
- The lack of tolerance development with chronic use supports its role in facilitating sustained physical activity for children.
- Montelukast provides a valuable pharmacologic strategy to manage EIB and improve quality of life for active children with asthma.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:24Antiasthma Drugs: Methylxanthines
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:13Asthma III: Clinical Manifestations
Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
01:30Asthma-IV: Nursing Management
The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
First, in...
01:30Asthma-IV: Diagnostic and Management
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes: